cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.15468/dl.awb2vg
title: Occurrence Download

description: A dataset containing 515 species occurrences available in GBIF matching the query:
{
 "and" : [
 "Country is one of (Czechia, Austria, Slovakia)",
 "Month is one of (March, April)",
 "OccurrenceStatus is Present",
 "TaxonKey is Carnivora",
 "Year 2024-2025"
 ]
}

 The dataset includes 515 records from 9 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0047190-251120083545085/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.ehmnt4
title: Occurrence Download

description: A dataset containing 515 species occurrences available in GBIF matching the query:
{
 "and" : [
 "Country is one of (Czechia, Austria, Slovakia)",
 "Month is one of (March, April)",
 "OccurrenceStatus is Present",
 "TaxonKey is Carnivora",
 "Year 2024-2025"
 ]
}

 The dataset includes 515 records from 9 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0047193-251120083545085/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.48597/2gd3-hx88
title: POPs (persistent organic pollutants) at Pallas (Matorova)

description: Measurement of POPs (persistent organic pollutants) at Pallas (Matorova)
DOI: 10.48597/43ax-cx27
title: POPs (persistent organic pollutants) at Pallas (Matorova)

description: Measurement of POPs (persistent organic pollutants) at Pallas (Matorova)
DOI: 10.48597/gqjc-6gev
title: POPs (persistent organic pollutants) at Pallas (Matorova)

description: Measurement of POPs (persistent organic pollutants) at Pallas (Matorova)
DOI: 10.48597/pfpm-7yy8
title: POPs (persistent organic pollutants) at Pallas (Matorova)

description: Measurement of POPs (persistent organic pollutants) at Pallas (Matorova)
DOI: 10.48597/qv5m-hcr8
title: POPs (persistent organic pollutants) at Pallas (Matorova)

description: Measurement of POPs (persistent organic pollutants) at Pallas (Matorova)
DOI: 10.48597/xbbg-bj3b
title: POPs (persistent organic pollutants) at Pallas (Matorova)

description: Measurement of POPs (persistent organic pollutants) at Pallas (Matorova)
DOI: 10.48597/3jv8-hhnk
title: POPs (persistent organic pollutants) at Pallas (Matorova)

description: Measurement of POPs (persistent organic pollutants) at Pallas (Matorova)
DOI: 10.48597/zm3r-8m4w
title: POPs (persistent organic pollutants) at Pallas (Matorova)

description: Measurement of POPs (persistent organic pollutants) at Pallas (Matorova)
DOI: 10.21227/va46-5s30
title: "Artificial Liver Treatment_imputed_data"

description: "The dataset used in the experiments is from an artificial liver dataset of a comprehensive tertiary hospital in Chengdu, containing clinical trial data of 206 patients. After excluding data features unrelated to patient treatment (such as total cost, western medicine income, traditional Chinese medicine income, registration income, consultation income, and examination income), the analysis data mainly includes 15 data covariates."
DOI: 10.48597/bsdt-fnbs
title: POPs (persistent organic pollutants) at Pallas (Matorova)

description: Measurement of POPs (persistent organic pollutants) at Pallas (Matorova)
DOI: 10.15468/dl.h9deu6
title: Occurrence Download

description: A dataset containing 469 species occurrences available in GBIF matching the query:
{
 "and" : [
 "Country is United Kingdom of Great Britain and Northern Ireland",
 "OccurrenceStatus is Present",
 "TaxonKey is one of (Ovis aries, Ovis aries, Ovis aries anglica)"
 ]
}

 The dataset includes 469 records from 32 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0047191-251120083545085/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.48597/ju8y-z8dv
title: POPs (persistent organic pollutants) at Pallas (Matorova)

description: Measurement of POPs (persistent organic pollutants) at Pallas (Matorova)
DOI: 10.48597/qzcr-xnc5
title: POPs (persistent organic pollutants) at Pallas (Matorova)

description: Measurement of POPs (persistent organic pollutants) at Pallas (Matorova)
DOI: 10.48597/dmk6-3egq
title: POPs (persistent organic pollutants) at Pallas (Matorova)

description: Measurement of POPs (persistent organic pollutants) at Pallas (Matorova)
DOI: 10.48597/fjfp-gdrk
title: PAHs (polycyclic aromatic hydrocarbons, 16) at Pallas (Matorova)

description: Measurement of PAHs (polycyclic aromatic hydrocarbons, 16) at Pallas (Matorova)
DOI: 10.48597/2wue-db2u
title: POPs (persistent organic pollutants) at Pallas (Matorova)

description: Measurement of POPs (persistent organic pollutants) at Pallas (Matorova)
DOI: 10.48597/5psb-6fcd
title: Copper at Vilsandi

description: Measurement of Copper at Vilsandi
DOI: 10.48597/73nv-w5g2
title: Zinc at Lahemaa

description: Measurement of Zinc at Lahemaa
DOI: 10.13140/rg.2.2.13943.89766
title: I have never accepted that limitation
DOI: 10.48597/8njt-ekeb
title: Lead at Lahemaa

description: Measurement of Lead at Lahemaa
DOI: 10.48597/e7y3-8n3z
title: Arsenic at Lahemaa

description: Measurement of Arsenic at Lahemaa
DOI: 10.48597/gdsy-a5sd
title: Precipitation_amount at Lahemaa

description: Measurement of Precipitation_amount at Lahemaa
DOI: 10.48597/kwqe-2gcq
title: Cadmium at Vilsandi

description: Measurement of Cadmium at Vilsandi
DOI: 10.48597/mpc5-4bsu
title: Lead at Vilsandi

description: Measurement of Lead at Vilsandi
DOI: 10.48597/payy-kf43
title: Copper at Lahemaa

description: Measurement of Copper at Lahemaa
DOI: 10.48597/phua-n9sr
title: Cadmium at Lahemaa

description: Measurement of Cadmium at Lahemaa
DOI: 10.48597/u39b-36r6
title: Precipitation_amount at Vilsandi

description: Measurement of Precipitation_amount at Vilsandi
DOI: 10.48597/3e4d-bt2y
title: Ozone at Vilsandi

description: Measurement of Ozone at Vilsandi
DOI: 10.48597/vrys-4c8d
title: Zinc at Vilsandi

description: Measurement of Zinc at Vilsandi
DOI: 10.48597/ey2n-gas2
title: Ozone at Lahemaa

description: Measurement of Ozone at Lahemaa
DOI: 10.48597/2z54-945r
title: Benzo_a_pyrene at Pallas (Matorova)

description: Measurement of Benzo_a_pyrene at Pallas (Matorova)
DOI: 10.48597/992n-q9tw
title: Precipitation_amount at Pallas (Matorova)

description: Measurement of Precipitation_amount at Pallas (Matorova)
DOI: 10.48597/3fzj-hgpb
title: PCB_138 at Pallas (Matorova)

description: Measurement of PCB_138 at Pallas (Matorova)
DOI: 10.48597/6b46-te2e
title: Anthracene at Pallas (Matorova)

description: Measurement of Anthracene at Pallas (Matorova)
DOI: 10.48597/bbq9-fgw7
title: Inden_123cd_pyrene at Pallas (Matorova)

description: Measurement of Inden_123cd_pyrene at Pallas (Matorova)
DOI: 10.48597/f2e5-3rpx
title: PCB_101 at Pallas (Matorova)

description: Measurement of PCB_101 at Pallas (Matorova)
DOI: 10.48597/g44w-w47k
title: PCB_28 at Pallas (Matorova)

description: Measurement of PCB_28 at Pallas (Matorova)
DOI: 10.48597/gg74-6w4z
title: Pp_DDD at Pallas (Matorova)

description: Measurement of Pp_DDD at Pallas (Matorova)
DOI: 10.48597/jywc-tz72
title: PCB_153 at Pallas (Matorova)

description: Measurement of PCB_153 at Pallas (Matorova)
DOI: 10.17026/ar/klfvpe
title: PAN-00179070 - rectangular/trapezium shaped single looped buckle

description: &lt;p&gt;This find is registered at Portable Antiquities of the Netherlands with number PAN-00179070&lt;/p&gt;
description: Modified: 2025-11-11T10:59:20+01:00
DOI: 10.48597/kt6g-jvjx
title: Pp_DDE at Pallas (Matorova)

description: Measurement of Pp_DDE at Pallas (Matorova)
DOI: 10.48597/mf6m-qqwb
title: PCB_118 at Pallas (Matorova)

description: Measurement of PCB_118 at Pallas (Matorova)
DOI: 10.48597/myds-vwm2
title: Benzo_k_fluoranthene at Pallas (Matorova)

description: Measurement of Benzo_k_fluoranthene at Pallas (Matorova)
DOI: 10.48597/pz66-p94g
title: PCB_52 at Pallas (Matorova)

description: Measurement of PCB_52 at Pallas (Matorova)
DOI: 10.48597/s5yu-5au4
title: Fluoranthene at Pallas (Matorova)

description: Measurement of Fluoranthene at Pallas (Matorova)
DOI: 10.48597/s738-394n
title: PCB_180 at Pallas (Matorova)

description: Measurement of PCB_180 at Pallas (Matorova)
DOI: 10.15468/dl.4gybdn
title: Occurrence Download

description: A dataset containing 0 species occurrences available in GBIF matching the query:
{"type":"and","predicates":[{"type":"within","geometry":"POLYGON ((119.47 -1.322819, 119.399718 -1.328384, 119.331166 -1.344945, 119.26603 -1.372093, 119.205914 -1.40916, 119.152297 -1.455234, 119.1065 -1.509181, 119.069649 -1.569672, 119.042653 -1.63522, 119.026177 -1.704211, 119.020628 -1.774945, 119.026144 -1.845682, 119.042589 -1.91468, 119.069561 -1.98024, 119.106396 -2.040747, 119.152188 -2.09471, 119.20581 -2.140801, 119.265942 -2.177883, 119.331102 -2.205042, 119.399684 -2.221611, 119.47 -2.227179, 119.540316 -2.221611, 119.608898 -2.205042, 119.674058 -2.177883, 119.73419 -2.140801, 119.787812 -2.09471, 119.833604 -2.040747, 119.870439 -1.98024, 119.897411 -1.91468, 119.913856 -1.845682, 119.919372 -1.774945, 119.913823 -1.704211, 119.897347 -1.63522, 119.870351 -1.569672, 119.8335 -1.509181, 119.787703 -1.455234, 119.734086 -1.40916, 119.67397 -1.372093, 119.608834 -1.344945, 119.540282 -1.328384, 119.47 -1.322819))"},{"type":"equals","key":"CLASS_KEY","value":"212","matchCase":false},{"type":"greaterThanOrEquals","key":"YEAR","value":"2015","matchCase":false},{"type":"not","predicate":{"type":"in","key":"BASIS_OF_RECORD","values":["MATERIAL_CITATION","MATERIAL_SAMPLE","PRESERVED_SPECIMEN"],"matchCase":false}},{"type":"lessThanOrEquals","key":"COORDINATE_UNCERTAINTY_IN_METERS","value":"10000","matchCase":false},{"type":"equals","key":"LICENSE","value":"CC BY 4.0","matchCase":false}]}

 The dataset includes 0 records from 0 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0047195-251120083545085/datasets/export for details.
DOI: 10.48597/ubja-wkzg
title: Pp_DDT at Pallas (Matorova)

description: Measurement of Pp_DDT at Pallas (Matorova)
DOI: 10.48597/vnmj-g2fq
title: Benzo_ghi_perylene at Pallas (Matorova)

description: Measurement of Benzo_ghi_perylene at Pallas (Matorova)
DOI: 10.48597/4t6w-cxbg
title: Nickel at Lahemaa

description: Measurement of Nickel at Lahemaa
DOI: 10.48597/xdqx-w6pa
title: Phenanthrene at Pallas (Matorova)

description: Measurement of Phenanthrene at Pallas (Matorova)
DOI: 10.48597/tc7e-cwrr
title: Mercury at Lahemaa

description: Measurement of Mercury at Lahemaa
DOI: 10.48597/amus-4hau
title: Mercury at Pallas (Matorova)

description: Measurement of Mercury at Pallas (Matorova)
DOI: 10.48597/wvpe-5b9e
title: Chromium at Lahemaa

description: Measurement of Chromium at Lahemaa
DOI: 10.48597/ctjh-azjb
title: BDE_100 at Pallas (Matorova)

description: Measurement of BDE_100 at Pallas (Matorova)
DOI: 10.48597/d9fa-gbtc
title: BDE_47 at Pallas (Matorova)

description: Measurement of BDE_47 at Pallas (Matorova)
DOI: 10.6084/m9.figshare.30861450
title: Simple implementation examples of agent AI on free energy calculation and phase-field simulation

description: With the development of an environment that equips large language models with tools, chat-type artificial intelligence (AI) is currently shifting to agent-type AI. Although building an agent AI with complex behavior is an important issue, a method for easily implementing simple agent AI is also useful in materials research. The objectives of this study are to demonstrate the usefulness of simple agent AI codes, and to distribute them as supplemental materials. The key points are summarized as follows. (1) Using Gibbs energy calculations as an example, we demonstrated a simple method for constructing agent AI, including explanation and distribution of the python code. (2) We applied this method to a scratch code development of phase-field simulation, and the template python code was also distributed. (3) Using the simple agent AI technique, we were able to easily verify that the Jarzynski equality is applicable for the diffusion behavior in diffusion couple, which provides a new approach for directly evaluating free energy change from diffusion flux information. Using Gibbs energy calculations and diffusion simulations as examples, we demonstrated the implementation method and usefulness of simple agent AI, where sample python codes are distributed as supplemental materials.
DOI: 10.6084/m9.figshare.30861450.v1
title: Simple implementation examples of agent AI on free energy calculation and phase-field simulation

description: With the development of an environment that equips large language models with tools, chat-type artificial intelligence (AI) is currently shifting to agent-type AI. Although building an agent AI with complex behavior is an important issue, a method for easily implementing simple agent AI is also useful in materials research. The objectives of this study are to demonstrate the usefulness of simple agent AI codes, and to distribute them as supplemental materials. The key points are summarized as follows. (1) Using Gibbs energy calculations as an example, we demonstrated a simple method for constructing agent AI, including explanation and distribution of the python code. (2) We applied this method to a scratch code development of phase-field simulation, and the template python code was also distributed. (3) Using the simple agent AI technique, we were able to easily verify that the Jarzynski equality is applicable for the diffusion behavior in diffusion couple, which provides a new approach for directly evaluating free energy change from diffusion flux information. Using Gibbs energy calculations and diffusion simulations as examples, we demonstrated the implementation method and usefulness of simple agent AI, where sample python codes are distributed as supplemental materials.
DOI: 10.48597/2epv-7sc3
title: BDE_99 at Pallas (Matorova)

description: Measurement of BDE_99 at Pallas (Matorova)
DOI: 10.48597/gt52-fwsp
title: Precipitation_amount at Pallas (Matorova)

description: Measurement of Precipitation_amount at Pallas (Matorova)
DOI: 10.48597/nf2n-qm9d
title: Mercury at Pallas (Matorova)

description: Measurement of Mercury at Pallas (Matorova)
DOI: 10.48597/47yh-pvqt
title: Nitrogen_dioxide at Eupen

description: Measurement of Nitrogen_dioxide at Eupen
DOI: 10.48597/4wp9-rdc5
title: Nitrogen_dioxide at Vezin

description: Measurement of Nitrogen_dioxide at Vezin
DOI: 10.6084/m9.figshare.29348140.v1
title: Hepatic arterial infusion chemotherapy in patients with unresectble hepatocellular carcinoma: 3-year survival update

description: Hepatic arterial infusion chemotherapy (HAIC) with oxaliplatin plus raltitrexed showed a promising response rate in patients with unresectable hepatocellular carcinoma (HCC) in a phase 2 trial. Here, we report the updated 3-year survival data after enrollment. In this prospective trial, we enrolled patients with intermediate and advanced unresectable HCC. The treatment was HAIC with raltitrexed plus oxaliplatin. The objective responses were achieved in 19 (48.7%) of 39 patients in the intention-to-treat population. The median overall survival and progress-free survival were 11.2 and 6.5 months, respectively. The 3-year survival update confirmed the antitumor activity and long-term survival benefit of HAIC with oxaliplatin plus raltitrexed in patients with unresectable HCC. www.chictr.org.cn identifier is ChiCTR-OOC-17014182. Hepatocellular carcinoma (HCC) is a leading cause of cancer – related deaths in China, with a large proportion of unresectable cases at diagnosis. Existing treatments like transcatheter arterial chemoembolization (TACE) and systemic therapies have limitations, and the optimal hepatic arterial infusion chemotherapy (HAIC) regimen is yet to be determined.Phase 2, single – arm, single – center, prospective clinical study on HAIC with oxaliplatin and raltitrexed for intermediate- and advanced-stage unresectable HCC.In the intention-to – treat population, 48.7% (19/39) achieved objective response, and 79.5% achieved disease control. In the per-protocol population, 54.3% achieved objective response and 88.6% achieved disease control.Median overall survival was 11.2 months, with 1-year, 2-year, and 3-year survival rates of 46.1, 30.7, and 30.7% respectively.Compared to systemic therapies like sorafenib, HAIC with oxaliplatin and raltitrexed showed a higher objective response rate, suggesting potential superiority in treating advanced HCC. Hepatocellular carcinoma (HCC) is a leading cause of cancer – related deaths in China, with a large proportion of unresectable cases at diagnosis. Existing treatments like transcatheter arterial chemoembolization (TACE) and systemic therapies have limitations, and the optimal hepatic arterial infusion chemotherapy (HAIC) regimen is yet to be determined. Phase 2, single – arm, single – center, prospective clinical study on HAIC with oxaliplatin and raltitrexed for intermediate- and advanced-stage unresectable HCC. In the intention-to – treat population, 48.7% (19/39) achieved objective response, and 79.5% achieved disease control. In the per-protocol population, 54.3% achieved objective response and 88.6% achieved disease control. Median overall survival was 11.2 months, with 1-year, 2-year, and 3-year survival rates of 46.1, 30.7, and 30.7% respectively. Compared to systemic therapies like sorafenib, HAIC with oxaliplatin and raltitrexed showed a higher objective response rate, suggesting potential superiority in treating advanced HCC.
DOI: 10.48597/6h5j-ntkr
title: Nitrogen_dioxide at Offagne

description: Measurement of Nitrogen_dioxide at Offagne
DOI: 10.48597/h7hk-yeqw
title: Ozone at Eupen

description: Measurement of Ozone at Eupen
DOI: 10.5281/zenodo.17899874
title: Cervical Cancer Dataset
DOI: 10.5281/zenodo.17899875
title: Cervical Cancer Dataset
DOI: 10.6084/m9.figshare.29348140
title: Hepatic arterial infusion chemotherapy in patients with unresectble hepatocellular carcinoma: 3-year survival update

description: Hepatic arterial infusion chemotherapy (HAIC) with oxaliplatin plus raltitrexed showed a promising response rate in patients with unresectable hepatocellular carcinoma (HCC) in a phase 2 trial. Here, we report the updated 3-year survival data after enrollment. In this prospective trial, we enrolled patients with intermediate and advanced unresectable HCC. The treatment was HAIC with raltitrexed plus oxaliplatin. The objective responses were achieved in 19 (48.7%) of 39 patients in the intention-to-treat population. The median overall survival and progress-free survival were 11.2 and 6.5 months, respectively. The 3-year survival update confirmed the antitumor activity and long-term survival benefit of HAIC with oxaliplatin plus raltitrexed in patients with unresectable HCC. www.chictr.org.cn identifier is ChiCTR-OOC-17014182. Hepatocellular carcinoma (HCC) is a leading cause of cancer – related deaths in China, with a large proportion of unresectable cases at diagnosis. Existing treatments like transcatheter arterial chemoembolization (TACE) and systemic therapies have limitations, and the optimal hepatic arterial infusion chemotherapy (HAIC) regimen is yet to be determined.Phase 2, single – arm, single – center, prospective clinical study on HAIC with oxaliplatin and raltitrexed for intermediate- and advanced-stage unresectable HCC.In the intention-to – treat population, 48.7% (19/39) achieved objective response, and 79.5% achieved disease control. In the per-protocol population, 54.3% achieved objective response and 88.6% achieved disease control.Median overall survival was 11.2 months, with 1-year, 2-year, and 3-year survival rates of 46.1, 30.7, and 30.7% respectively.Compared to systemic therapies like sorafenib, HAIC with oxaliplatin and raltitrexed showed a higher objective response rate, suggesting potential superiority in treating advanced HCC. Hepatocellular carcinoma (HCC) is a leading cause of cancer – related deaths in China, with a large proportion of unresectable cases at diagnosis. Existing treatments like transcatheter arterial chemoembolization (TACE) and systemic therapies have limitations, and the optimal hepatic arterial infusion chemotherapy (HAIC) regimen is yet to be determined. Phase 2, single – arm, single – center, prospective clinical study on HAIC with oxaliplatin and raltitrexed for intermediate- and advanced-stage unresectable HCC. In the intention-to – treat population, 48.7% (19/39) achieved objective response, and 79.5% achieved disease control. In the per-protocol population, 54.3% achieved objective response and 88.6% achieved disease control. Median overall survival was 11.2 months, with 1-year, 2-year, and 3-year survival rates of 46.1, 30.7, and 30.7% respectively. Compared to systemic therapies like sorafenib, HAIC with oxaliplatin and raltitrexed showed a higher objective response rate, suggesting potential superiority in treating advanced HCC.
DOI: 10.6084/m9.figshare.30426506
title: Qualitative research to understand the patient experience with advanced and/or metastatic hepatocellular carcinoma

description: The present study aimed to explore the patient experience in advanced and/or metastatic hepatocellular carcinoma (HCC). A multi-phase research design was followed that included a targeted literature review (TLR), interviews with clinicians, and interviews with patients. Patient interviews were analyzed using an iterative, thematic analysis approach. An assessment of the conceptual saturation of all spontaneously patient-reported signs and symptoms was conducted. Ten patient-centric qualitative studies were identified in the TLR. Five United States (US) clinicians and 15 US patients participated in semi-structured interviews, conducted via video conferencing, lasting approximately 60 minutes each. The five most commonly reported symptoms were fatigue, weight loss, weakness, reduction in appetite, and sleep disturbance. Furthermore, HCC impacted all aspects of patients’ lives, including physical functioning, social and family functioning, emotional functioning, physical activities, and activities of daily living. The concepts were mostly similar across the different data sources. A patient-centric conceptual model was developed based on the TLR and patient interviews. The study provides an in-depth description of signs/symptoms and impacts in advanced and/or metastatic HCC that can support the identification of suitable patient-reported outcome measures. Separate investigation is needed to distinguish between disease impacts and treatment impacts. We wanted to learn how people with liver cancer live with their cancer. In this study, we looked at liver cancer that is advanced and/or liver cancer that has spread to other parts of the body outside of the liver. We read articles in science journals and talked with five liver cancer doctors and 15 people with liver cancer. We talked to each person for about one hour and recorded our call. Afterwards, we wrote down what people said during the call and read it. We wanted to know how people with liver cancer felt day-to-day and how their liver cancer changed how well they could do what they wanted to do. People with liver cancer most often felt tired and weak, lost weight, had trouble sleeping, and were less hungry than they were before they got liver cancer. Because of their liver cancer, people could not move their bodies like they wanted to (like walking or playing sports), had to change what they did with friends and family, felt sad and worried, and had trouble doing day-to-day tasks, like chores and shopping. A few people also had less money, had to go on sick leave, or had to retire earlier than they would have liked. This study helped us to better understand what it’s like for people to live with liver cancer. It may help people working in health care to better understand how people with liver cancer feel.